Literature DB >> 11791179

Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences.

Yoshiaki Adachi1, Nirmala Chandrasekar, Yoshiaki Kin, Sajani S Lakka, Sanjeeva Mohanam, Niranjan Yanamandra, Pamarthi M Mohan, Gregory N Fuller, Bingliang Fang, Juan Fueyo, Dzung H Dinh, William C Olivero, Takashi Tamiya, Takashi Ohmoto, Anthanassios P Kyritsis, Jasti S Rao.   

Abstract

Our previous studies showed that the urokinase-type plasminogen activator receptor (uPAR) and the p16 tumor suppressor gene play a significant role in glioma invasion. We expected that downregulation of uPAR and overexpression of p16 using a bicistronic vector might cause a additive and cooperative effect in the suppression of glioma invasion and growth. The bicistronic construct (Ad-uPAR/p16)-infected glioblastoma cell lines had significantly lower levels of uPAR and higher levels of p16 than controls. Cell cycle analysis showed the bicistronic vector caused G0/G1 arrest of the cell cycle. In vitro glioblastoma cell growth and invasiveness were inhibited in Ad-uPAR/p16-infected cells compared with controls. Ad-uPAR/p16 suppressed the tumor growth of glioblastoma cell lines in an ex vivo intracerebral tumor model and an in vivo subcutaneous tumor model. Our results support the therapeutic potential of simultaneously targeting uPAR and p16 in the treatment of gliomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11791179     DOI: 10.1038/sj.onc.1204999

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

Review 1.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

2.  Sense p16 and antisense uPAR bicistronic construct inhibits angiogenesis and induces glioma cell death.

Authors:  Narasimharao Nalabothula; Sajani S Lakka; Dzung H Dinh; Meena Gujrati; William C Olivero; Jasti S Rao
Journal:  Int J Oncol       Date:  2007-03       Impact factor: 5.650

3.  A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.

Authors:  Jill Wykosky; Jingjing Hu; German G Gomez; Tiffany Taylor; Genaro R Villa; Donald Pizzo; Scott R VandenBerg; Amy Haseley Thorne; Clark C Chen; Paul S Mischel; Steven L Gonias; Webster K Cavenee; Frank B Furnari
Journal:  Cancer Res       Date:  2014-11-28       Impact factor: 12.701

4.  Inhibition of the proprotein convertases represses the invasiveness of human primary melanoma cells with altered p53, CDKN2A and N-Ras genes.

Authors:  Claude Lalou; Nathalie Scamuffa; Samia Mourah; Francois Plassa; Marie-Pierre Podgorniak; Nadem Soufir; Nicolas Dumaz; Fabien Calvo; Nicole Basset-Seguin; Abdel-Majid Khatib
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

Review 5.  EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment.

Authors:  Stefanie Keller; Mirko H H Schmidt
Journal:  Int J Mol Sci       Date:  2017-06-18       Impact factor: 5.923

Review 6.  Current Approaches for Glioma Gene Therapy and Virotherapy.

Authors:  Kaushik Banerjee; Felipe J Núñez; Santiago Haase; Brandon L McClellan; Syed M Faisal; Stephen V Carney; Jin Yu; Mahmoud S Alghamri; Antonela S Asad; Alejandro J Nicola Candia; Maria Luisa Varela; Marianela Candolfi; Pedro R Lowenstein; Maria G Castro
Journal:  Front Mol Neurosci       Date:  2021-03-11       Impact factor: 5.639

7.  Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.

Authors:  Swapna Asuthkar; Victoria Stepanova; Tatiana Lebedeva; Aixuan L Holterman; Norman Estes; Douglas B Cines; Jasti S Rao; Christopher S Gondi
Journal:  Mol Biol Cell       Date:  2013-07-17       Impact factor: 4.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.